 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
|
|
| |
| Company Profile |
| |
|
Cerus Corporation develops products for cancer, infectious disease, and blood safety. It develops cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens. The company is also developing the INTERCEPT Blood System, which is based on the companys Helinx technology for controlling biological replication. The INTERCEPT Blood System is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, other pathogens, and white blood cells. This system targets and inactivates blood-borne pathogens, such as HIV and hepatitis B and C, as well as harmful white blood cells, while leaving the therapeutic properties of the blood components intact. Cerus is also developing a proprietary vaccine platform to stimulate the immune system to target and attack cancer cells and infectious diseases. It has three therapeutic cancer vaccine products in development using its Listeria vaccine platform: one in collaboration with MedImmune, Inc. to treat cancers of the breast, prostate, and colon, as well as metastatic melanomas; and two with The Johns Hopkins University. In addition, the company has collaboration agreements with Baxter Healthcare Corporation and BioOne Corporation for the joint development of the INTERCEPT Blood System for platelets and plasma. Cerus was incorporated in 1991 and is based in Concord, California.
|
CERUS CORP Related |
|
Cerus - Develops systems designed to improve safety of blood transfusions by inactivating infectious pathogens in blood components, platelets, fresh frozen plasma and red ...
|
|
CERS: CERUS CORP Stock Quote Research CERUS CORP historical prices, historical volume, splits and dividends. ... Get the latest CERUS CORP stock information on the web. ...
|
|
CERS: Headlines for CERUS CORP - Yahoo! Finance Find out the latest news headlines for CERUS CORP (CERS) ... CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, ...
|
|
|
|
|
